

# PHARMACY POLICY STATEMENT

## Marketplace

DRUG NAME	Abecma (idecabtagene vicleucel )
BILLING CODE	Q2055
BENEFIT TYPE	Medical
SITE OF SERVICE ALLOWED	Inpatient/Outpatient hospital
STATUS	Prior Authorization Required

Abecma is a B-cell maturation antigen (BCMA)-directed, autologous chimeric(0.00.(i)-1.1 (c) )Murat 0.038 T 0 Td cells to target and kill them. Abecma was approved in March 2021 relapsed or refractory multiple myeloma after 4 or more prior therapies plasma cells in the bone marrow. Abecma is the first CAR-T therapy a first to target the BCMA protein, whereas existing products target the

Abecma (idecabtagene vicleucel) will be considered for coverage when the following criteria are met:

### Multiple Myeloma

For initial authorization:

1. Member is at least 18 years of age; AND
2. Healthcare facility/provider has enrolled in the Abecma REMS program; AND
3. Member has a diagnosis of relapsed or refractory multiple myeloma (RRMM); AND
4. Member has persistent disease after treatment with 4 or more prior lines of therapy, including ALL the following:
  - a) An immunomodulatory agent (e.g. Revlimid),
  - b) A proteasome inhibitor (e.g. Velcade), and
  - c) An anti-CD38 monoclonal antibody (e.g. Darzalex); AND
5. Member has an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1.

CareSource considers Abecma (idecabtagene vicleucel ) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off- Label policy.

